Reaction
Cholangitis Infective reporting signals
As of the last recalculation, Cholangitis Infective appears in 259 FAERS reports alongside 14 co-occurring drug terms. The strongest observed disproportionality signal is DURVALUMAB (PRR 99.6).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Durvalumab | 23 | 99.6 | 99.7 |
| Pegaspargase | 12 | 82.5 | 82.6 |
| Basiliximab | 10 | 71.0 | 71.1 |
| Gemcitabine | 28 | 63.9 | 64.0 |
| Tobramycin Solution | 9 | 62.3 | 62.4 |
| Gemcitabine Hydrochloride | 35 | 61.1 | 61.2 |
| Tobramycin Sulfate | 9 | 60.5 | 60.5 |
| Amphotericin B | 8 | 52.9 | 53.0 |
| Piperacillin Sodium,Tazobactam Sodium | 15 | 48.2 | 48.2 |
| Irinotecan Hydrochloride | 7 | 44.9 | 45.0 |
| Erlotinib | 4 | 33.7 | 33.7 |
| Erlotinib Hydrochloride | 5 | 32.7 | 32.7 |
| Tobramycin | 9 | 31.1 | 31.1 |
| Atezolizumab | 10 | 21.5 | 21.5 |